1 Report Prologue 14 2 Introduction 15 2.1 Scope of Study 15 2.2 Research Objective 15 2.3 Assumptions & Limitations 15 2.3.1 Assumptions 15 2.3.2 Limitations 16 2.4 Market Structure 16 3 Research Methodology 17 3.1 Research Process 17 3.2 Primary Research 18 3.3 Secondary Research 18 4 Market Dynamics 19 4.1 Introduction 19 4.2 Drivers 19 4.2.1 Comparatively painless and non-invasive technique 19 4.2.2 Early real time high precision detection of diseases 19 4.2.3 Useful for designing effective treatment strategies based on the real time molecular assessment for the progression of the disease 19 4.2.4 Rise in cases of cancer and other diseases 20 4.2.5 Lifestyle changes and environmental factors 20 4.2.6 Other advantages over other techniques 20 4.2.7 The recent technological advancements has increased the appeal of liquid biopsy 20 4.2.8 Transferability of liquid biopsy 21 4.2.9 Rising investment in research and development and collaborations between companies and public organizations 21 4.2.10 Greater focus on venture capital 21 4.2.11 Demographical factors 21 4.3 Restraints 22 4.3.1 Prohibitive costs associated with liquid biopsy 22 4.3.2 Lower sensitivity for certain biomarkers 22 4.3.3 Not all cancers patients benefit from early detection 22 4.3.4 Liquid biopsy is not all non-invasive 22 4.3.5 Differential awareness and availability between developing and developed world 22 4.3.6 Issues in venture capital, startups and collaborations 23 4.4 Opportunities 23 4.4.1 Growing collaboration between companies has become the entrance gateway for new firms 23 4.4.2 Funding from public organizations is a good strategy to reduce development costs 23 4.4.3 Rise in research and development investment 23 4.4.4 Developing economies provide an unserved market for liquid biopsy 23 4.4.5 Growing trend of start-ups and venture investment in the field of liquid biopsy 24 4.5 Challenges 24 4.5.1 Information and interest gap between the investors and the developers 24 4.5.2 Lack of trained professionals in developing regions 24 4.5.3 Lack of standardization and transparency 24 5 Market Factor Analysis 26 5.1 Porter’s Five Force Analysis 26 5.1.1 Bargaining Power of Buyer 27 5.1.2 Bargaining Power of Supplier 28 5.1.3 Threat from substitute 28 5.1.4 Threat from a New Entrant 28 5.1.5 Intensity of Competitive Rivalry 28 5.2 Value Chain Analysis 29 5.2.1 Device Manufacturers 30 5.2.2 Software developers 30 5.2.3 Reagent and accessory suppliers 30 5.2.4 Healthcare providers 30 5.2.5 Patients 30 6 Liquid Biopsy Market, By Biomarker Types 31 6.1 Introduction 32 6.2 Circulating Tumor Cells (CTCs) 33 6.3 Circulating Tumour DNA (CtDNA) 34 6.4 Extracellular Vesicles (EVs) 35 6.5 Other biomarker (circulating RNA and proteins) 36 7 Global Liquid Biopsy Market by Application 38 7.1 Introduction 38 7.2 Cancer therapeutic application 39 7.3 Reproductive health 40 7.4 Other therapeutic application market 41 8 Global Liquid Biopsy Market by Sample 43 8.1 Introduction 43 8.2 Blood Sample market, by region, 2015 & 2022 ($ million) 44 8.3 Urine sample market, by region, 2015 & 2022 ($ million) 45 8.4 Other sample market, by region, 2015 & 2022 ($ million) 46 9 Global Liquid Biopsy Market by End User 48 9.1 Introduction 48 9.2 Hospitals and Laboratories End Users, By Region 49 9.3 Academic and Research Centres end users market 50 9.4 Other end users market 51 10 Global liquid Biopsy Market, by Region 53 10.1 Introduction 53 10.2 North North America 54 10.2.1 US 59 10.2.2 CANADA 63 10.3 EUROPE 67 10.3.1 Germany 72 10.3.2 France 76 10.3.3 U.K. 80 10.3.4 Italy 84 10.3.5 Spain 88 10.3.6 Rest of Europe 92 10.4 APEC 97 10.4.1 Japan 103 10.4.2 China 107 10.4.3 India 111 10.4.4 Australia 115 10.4.5 Korea 119 10.4.6 Rest of Asia Pacific 123 10.5 Middle East and Africa 127 10.5.1 UAE 132 10.5.2 Saudi Arabia 136 10.5.3 Egypt 140 10.5.4 Rest of Middle East and Africa 144 11 Company Profile 149 11.1 Guardant Health, Inc 149 11.1.1 Company Overview 149 11.1.2 Product/Business Segment Overview 149 11.1.3 Financial Overview 149 11.1.4 Key Development 150 11.1.5 SWOT Analysis 151 11.2 Trovagene, Inc 152 11.2.1 Company Overview 152 11.2.2 Product/Business Segment Overview 152 11.2.3 Financial Overview 152 11.2.4 SWOT Analysis 153 11.3 RainDance Technologies, Inc. 155 11.3.1 Company Overview 155 11.3.2 Product/Business Segment Overview 155 11.3.3 Financial Overview 155 11.3.4 Key Development 155 11.3.5 SWOT Analysis 156 11.4 Agena Bioscience Inc. Inc. 157 11.4.1 Company Overview 157 11.4.2 Product/Business Segment Overview 157 11.4.3 Financial Overview 157 11.4.4 Key Development 157 11.5 Admera Health 159 11.5.1 Company Overview 159 11.5.2 Product/Business Segment Overview 159 11.5.3 Financial Overview 159 11.5.4 Key Development 159 11.5.5 SWOT Analysis 159 11.6 Biocept, Inc. 161 11.6.1 Company Overview 161 11.6.2 Product/Business Segment Overview 161 11.6.3 Financial Overview 161 11.6.4 Key Development 161 11.7 Circulogene Theranostics 162 11.7.1 Company Overview 162 11.7.2 Financial Overview 162 11.7.3 Key Development 162 11.8 Inivata Ltd 163 11.8.1 Company Overview 163 11.8.2 Product/Business Segment Overview 163 11.8.3 Financial Overview 163 11.8.4 Key Development 163 11.9 SAGA Diagnostics AB 164 11.9.1 Company Overview 164 11.9.2 Product/Business Segment Overview 164 11.9.3 Financial Overview 164 11.9.4 Key Development 164 11.10 Exosome Diagnostics 165 11.10.1 Company Overview 165 11.10.2 Financial Overview 165 11.10.3 Key Development 165